Poseida Therapeutics, Inc. Proceeds from Common Stock Issued
Poseida Therapeutics, Inc. reported Proceeds from Common Stock Issued of $928.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-07.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2024-11-07
- Poseida Therapeutics, Inc. proceeds from issuance of common stock for the quarter ending 2023-12-31 was $0.00.
- Poseida Therapeutics, Inc. proceeds from issuance of common stock for the quarter ending 2023-09-30 was $0.00.
- Poseida Therapeutics, Inc. proceeds from issuance of common stock for the quarter ending 2023-06-30 was $0.00.
- Poseida Therapeutics, Inc. proceeds from issuance of common stock for the quarter ending 2023-03-31 was $928.00K.
- Poseida Therapeutics, Inc. proceeds from issuance of common stock for fiscal 2023 was $928.00K, a 98.77% decline from fiscal 2022.
- Poseida Therapeutics, Inc. proceeds from issuance of common stock for fiscal 2022 was $75.30M.
| Period end | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $0.00 derived: sum of 3 quarters · filed 2024-11-07 | $928.00K 10-K · filed 2024-03-07 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $928.00K 10-Q · filed 2024-11-07 | $928.00K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $928.00K 10-Q · filed 2024-08-05 | $928.00K derived: sum of 3 quarters · filed 2024-08-05 | |
| 2023-03-31 | $928.00K 10-Q · filed 2024-05-14 | $928.00K derived: sum of 2 quarters · filed 2024-05-14 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $75.30M 10-K · filed 2023-03-09 | ||
| 2022-09-30 | $75.30M 10-Q · filed 2022-11-10 |